Bone turnover markers as surrogates of fracture healing after intramedullary fixation of tibia and femur fractures.
| dc.contributor.author | Stewart, Christopher C | |
| dc.contributor.author | O'Hara, Nathan N | |
| dc.contributor.author | Bzovsky, Sofia | |
| dc.contributor.author | Bahney, Chelsea S | |
| dc.contributor.author | Sprague, Sheila | |
| dc.contributor.author | Slobogean, Gerard P | |
| dc.date.accessioned | 2022-05-19T11:16:53Z | |
| dc.date.available | 2022-05-19T11:16:53Z | |
| dc.date.issued | 2022-04 | |
| dc.identifier.uri | http://hdl.handle.net/10713/18923 | |
| dc.description.abstract | A total of 102 participants aged 18 to 50 years (median 28 years (interquartile range 23 to 35)), receiving an intramedullary nail for a tibial or femoral shaft fracture, were enrolled in a randomized controlled trial comparing vitamin D3 supplementation to placebo. Serum C-terminal telopeptide of type I collagen (CTX; bone resorption marker) and N-terminal propeptide of type I procollagen (P1NP; bone formation marker) were measured at baseline, six weeks, and 12 weeks post-injury. Clinical and radiological fracture healing was assessed at three months. | en_US |
| dc.description.uri | https://doi.org/10.1302/2046-3758.114.BJR-2021-0226.R1 | en_US |
| dc.description.uri | http://www.ncbi.nlm.nih.gov/pmc/articles/pmc9057525/ | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | British Editorial Society of Bone & Joint Surgery | en_US |
| dc.relation.ispartof | Bone & Joint Research | en_US |
| dc.subject | Bone turnover marker | en_US |
| dc.subject | Bone turnover markers | en_US |
| dc.subject | CTX | en_US |
| dc.subject | Fracture | en_US |
| dc.subject | P1NP | en_US |
| dc.subject | Serum | en_US |
| dc.subject | Vitamin D | en_US |
| dc.subject | femoral shaft fractures | en_US |
| dc.subject | femur fractures | en_US |
| dc.subject | fracture healing | en_US |
| dc.subject | randomized controlled trial | en_US |
| dc.subject | tibia | en_US |
| dc.subject | type I collagen | en_US |
| dc.title | Bone turnover markers as surrogates of fracture healing after intramedullary fixation of tibia and femur fractures. | en_US |
| dc.type | Article | en_US |
| dc.identifier.doi | 10.1302/2046-3758.114.BJR-2021-0226.R1 | |
| dc.identifier.pmid | 35442058 | |
| dc.source.journaltitle | Bone & joint research | |
| dc.source.volume | 11 | |
| dc.source.issue | 4 | |
| dc.source.beginpage | 239 | |
| dc.source.endpage | 250 | |
| dc.source.country | England |
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
Fracture Strength of Repaired Midline Fractures of Maxillary DentureStatement of problem: Denture fracture is a frequent clinical problem faced by the dentist. Denture repair should be simple to perform, cost-effective and quick. Unfortunately, the current methods of repair do not meet all of these requirements. Cyanoacrylate is a conveniently available adhesive material and it has been used by some patients to temporarily repair dentures before they get new ones. It is easy to use and relatively inexpensive. However, there is no literature that lists cyanoacrylate as a type of denture repair material. Purpose: This study investigated the transverse fracture strength of denture bases repaired with cyanoacrylates (Loctite Superglue Liquid, Loctite Superglue Liquid Professional). This was compared with denture bases repaired with auto-polymerizing acrylic resin (Lucitone 199 Repair Material). Material and methods: Thirty maxillary denture specimens were prepared and tested. They were divided into 3 different groups. Each of them was prepared with a clean midline fracture, repaired with Loctite Superglue Liquid, Loctite Superglue Liquid Professional or Lucitone 199 Repair Material and tested using the Universal Testing Machine. Data were analyzed using 1-way ANOVA and Tukey's HSD test, α=0.05. Results: There was a significant difference among the 3 types of repair materials. There was no significant difference in transverse fracture strength between Loctite Superglue Liquid Professional (107.16 ±20.57 MPa) and Lucitone 199 Repair Material (128.90 ±22.08 MPa). Loctite Superglue Liquid (53.79 ±19.05 MPa) had significant less transverse fracture strength than the other 2 types of material. Conclusion: Within the limitations of this study, cyanoacrylate containing methyl methacrylate polymer (Loctite Superglue Liquid Professional) is an inexpensive and readily available material which can be used as a temporary measure to repair dentures with a clean fracture. However, further studies are required to investigate the long term cytotoxicity and intraoral stability of the material.
-
Fixation using Alternative Implants for the Treatment of Hip Fractures (FAITH-2): The Exploratory Health-Related Quality of Life and Patient-Reported Functional Outcomes of a Multi-Centre 2 × 2 Factorial Randomized Controlled Pilot Trial in Young Femoral Neck Fracture Patients.Patients between the ages of 18-60 years with a femoral neck fracture requiring surgical fixation were eligible. Eligible patients were randomized to receive either a sliding hip screw or cancellous screws for fracture fixation AND vitamin D3 4,000 IU or placebo daily for 6 months. Patient-reported function (Hip Outcome Score) and HRQL (Short Form-12) were assessed at standardized time points in the 12 months following their fixation surgery. Patient-reported function and HRQL were summarized using means, SD, and 95% confidence intervals (CIs), or percentages and counts. Longitudinal data analysis with mixed models was used to explore the effect of treatment group and time on the patient-reported function and HRQL.
-
Fixation using alternative implants for the treatment of hip fractures (FAITH-2): Design and rationale for a pilot multi-centre 2 x 2 factorial randomized controlled trial in young femoral neck fracture patientsBackground: Femoral neck fractures in patients . 60 years of age are often very different injuries compared to low-energy, hip fractures in elderly patients and are difficult to manage because of inherent problems associated with high-energy trauma mechanisms and increased functional demands for recovery. Internal fixation, with multiple cancellous screws or a sliding hip screw (SHS), is the most common treatment for this injury in young patients. However, there is no clinical consensus regarding which surgical technique is optimal. Additionally, there is compelling rationale to use vitamin D supplementation to nutritionally optimize bone healing in young patients. This pilot trial will determine feasibility and provide preliminary clinical data for a larger definitive trial. Methods: We will conduct a multicenter, concealed randomized controlled pilot study, using a 2 ~ 2 factorial design in 60 patients aged 18.60 years with a femoral neck fracture. Eligible patients will be randomized in equal proportions to one of four groups: 1) SHS and vitamin D supplementation (4000 international units (IU) daily dose) for 6 months, 2) cancellous screws and vitamin D supplementation (4000 IU daily dose) for 6 months, 3) SHS and placebo, and 4) cancellous screws and placebo. Participants will be followed for 12 months post-fracture. Feasibility outcomes include initiation of clinical sites, recruitment, follow-up, data quality, and protocol adherence. Clinical outcomes, for both the pilot and planned definitive trials, include a composite of patient-important outcomes (re-operation, femoral head osteonecrosis, severe femoral neck malunion, and nonunion), health-related quality of life and patient-reported function, fracture healing complications, and radiographic fracture healing. A priori success criteria have been established. If the pilot study is deemed successful, study participants will be included in the definitive trial and clinical outcomes for the pilot will not be analyzed. If the pilot study is not deemed successful, clinical outcome data will be analyzed. Discussion: Results of this study will inform the feasibility of a definitive trial. If clinical outcome data are analyzed, they will be disseminated through a publication and presentations. Trial registration: The FAITH-2 trial, described as a definitive trial, was registered at ClinicalTrials.gov (NCT01908751) prior to enrollment of the first participant. Copyright The Author(s).
